跳至主要内容
临床试验/ISRCTN78539530
ISRCTN78539530已完成未知

A single-centre randomised controlled pilot trial to assess the feasibility of a definitive trial of the clinical effectiveness and cost effectiveness of the HF Manual in patients with heart failure with preserved ejection fraction and their caregivers (REACH-HFpEF)

Royal Cornwall Hospitals NHS Trust0 个研究点目标入组 50 人开始时间: 2015年8月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

2016 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/27798024 protocol 2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29632081 results (added 29/01/2019) 2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/33407893/ process evaluation (added 12/01/2021) 2023 Other publications in https://pubmed.ncbi.nlm.nih.gov/36759035/ Secondary analysis (added 10/02/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male or female aged =18 years
  • 2. Patients with heart failure, defined by the presence of at least one of the following symptoms at the time of screening:
  • 2.1. Paroxysmal nocturnal dyspnoea
  • 2.2. Orthopnoea
  • 2.3. Dyspnoea on mild or moderate exertion
  • AND at least one of the following signs prior to study entry:
  • 2.4. Basal crepitations
  • 2.5. Elevated jugular venous pressure
  • 2.6. Lower extremity oedema
  • 2.7. Chest radiograph demonstrating pleural effusion, pulmonary congestion or cardiomegaly
  • 3. Patients with left ventricular ejection fraction (EF) =45% obtained within 6 months prior to randomization and after any myocardial infarction (MI) or other event that would affect EF (ideally obtained by echocardiography, although radionuclide ventriculography and angiography are acceptable)
  • 4. Provision of informed consent to participate.

排除标准

  • 1. Patients who have undertaken cardiac rehabilitation (CR) within the last six months
  • 2. Patients with severe chronic pulmonary disease defined as requiring home oxygen or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the opinion of the investigator
  • 3. Patients who have any of the following contraindications to exercise testing or exercise training (adapted from ESC HF guidelines) documented in their medical notes:
  • 3.1. Early phase after acute coronary syndrome (up to 2 days)
  • 3.2. Untreated life-threatening cardiac arrhythmias
  • 3.3. Acute heart failure (during the initial period of haemodynamic instability)
  • 3.4. Uncontrolled hypertension (SBP >200 and/or DBP >100)
  • 3.5. Advanced atrioventricular block
  • 3.6. Acute myocarditis and pericarditis
  • 3.7. Symptomatic aortic stenosis
  • 3.8. Severe hypertrophic obstructive cardiomyopathy
  • 3.9. Acute systemic illness
  • 3.10. Intracardiac thrombus
  • 3.11. Progressive worsening of exercise tolerance or dyspnoea at rest over previous 3–5 days
  • 3.12. Significant ischaemia during low-intensity exercise (<2 METs, <50 W)
  • 3.13. Uncontrolled diabetes (blood glucose >16 mmol/l or HbA1C >9% or equivalent unit)
  • 3.14. Recent embolism
  • 3.15. Thrombophlebitis
  • 3.16. Recent-onset atrial fibrillation/atrial flutter (in the last 4 weeks)
  • 4. Patients who are unable to understand the study information or unable to complete study procedures
  • 5. Patients who are in a long-term care establishment or who are unwilling or unable to travel to research assessments or accommodate home visits
  • 6. Patients judged to be unable to participate in the study for any other reason, e.g. psychiatric disorder, diagnosis of dementia, life-threatening co-morbidity
  • 7. Patients participating in concurrent interventional research which may over-burden the patient or confound data collection

研究者

相似试验

Rehabilitation enablement in chronic heart failure | 临床试验